Condition: Cirrhosis, Liver · Sponsor: University of Texas Southwestern Medical Center
This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.
This description comes directly from the study's public registry record.
Yujin Hoshida, MD, PhD · 214-648-3111 · yujin.hoshida@utsouthwestern.edu
Always discuss trial participation with your own doctor first.
| UT Southwestern | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06015022